Responses
Clinical and epidemiological research
Extended report
Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial
Compose a Response to This Article
Other responses
No responses have been published for this article.